HCWB Profile
HCW Biologics Inc. is a preclinical-stage biopharmaceutical company dedicated to the discovery and development of innovative immunotherapies targeting chronic, low-grade inflammation and age-related diseases. The company is focused on advancing its proprietary therapies designed to address a range of serious health conditions through novel immunomodulatory approaches.
HCW Biologics’ lead product candidate, HCW9218, is an injectable immunotherapeutic designed to treat various types of cancer, including pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis. This product represents a significant advancement in immunotherapy, aiming to offer new treatment options for patients with these challenging conditions. Another key product, HCW9302, is under development for the treatment of autoimmune diseases such as alopecia areata, and metabolic disorders, expanding the company's focus beyond oncology.
The company's pipeline also includes HCW9201, a cell-based therapy currently in Phase II clinical trials. HCW9201 is being evaluated for its effectiveness in treating relapsed or refractory acute myeloid leukemia (AML), a severe and difficult-to-treat form of leukemia. In addition, HCW9206 is another promising therapy in development specifically targeting acute myeloid leukemia, further demonstrating HCW Biologics' commitment to addressing hematologic malignancies.
Founded in 2018 and headquartered in Miramar, Florida, HCW Biologics Inc. is committed to leveraging cutting-edge science to develop therapies that address significant unmet medical needs. The company's focus on immunotherapy and its diverse pipeline underscore its dedication to advancing treatment options for complex diseases and improving patient outcomes through innovative biopharmaceutical solutions.
|
